Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-450/r, ABT-333, or ABT-072 + PegIFN/RBV in HCV Genotype 1
NCT01074008Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2010
- Primary completion
- Jun 2011
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of paritaprevir, dasabuvir, ABT-072 in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Mar 2010; status: completed.
02
Drugs
paritaprevirdasabuvirABT-072
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01074008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01074008.